Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results - Second quarter DAYBUE ® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID ® GAAP net sales of $183 million, up 10% year-over-ye
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised full-year revenue range and the specified Phase 2 topline window for remlifanserin, plus regulatory milestones (FDA Fast Track for remlifanserin and a positive EMA CHMP opinion for DAYBUE in Rett syndrome).
Market read
This is a primary earnings-and-guidance disclosure with a near-term pipeline readout window, which can drive repricing ahead of the next catalyst.
What to watch
R&D and SG&A are rising year over year, and the key pipeline catalyst is still pending; investors may discount near-term impact until topline data is released.
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
GAAP total revenues grew 16% year-over-year to $308 million, DAYBUE GAAP net sales grew 30%, net income increased to $32 million, and the company raised full-year total-revenue and DAYBUE sales guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $308M | – | up 16% |
| Adjusted total revenues comparisonnon-GAAP | $262M | – | – |
| Research and development expensesGAAP | $82M | – | – |
| Selling, general and administrative expensesGAAP | $160M | – | – |
| Net incomeGAAP | $32M | – | – |
| Diluted earnings per shareGAAP | $0.18 per diluted share | – | – |
| Cash, cash equivalents, and investment securitiesGAAP | $956M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| NUPLAZIDThe company cited strong momentum, especially in new-to-brand prescriptions, as its recently expanded sales force gained traction in the field. | $183M | – | up 9% |
| DAYBUEContinued patient demand and robust uptake of DAYBUE STIX drove performance. | $125M | – | an increase of 30% |
Full Year 2026 Financial Guidance (GAAP) outlook
- Revenue$1.24 to $1.30 billion
- NoteNUPLAZID net product sales in the range of $760 to $790 million.
- NoteDAYBUE (including all forms of trofinetide) global net product sales in the range of $480 to $510 million.
- NoteR&D expense in the range of $355 to $380 million.
- NoteSG&A expense in the range of $660 to $700 million.
What drove it
- GAAP total revenues were driven by net product sales from NUPLAZID and DAYBUE.
- DAYBUE performance reflected continued patient demand and robust uptake of DAYBUE STIX.
- NUPLAZID new-to-brand prescription momentum was supported by the recently expanded sales force.
- The company completed enrollment in the Phase 2 portion of the RADIANT program and initiated Phase 3 screening and enrollment.
- CHMP adopted a positive opinion recommending marketing authorization for DAYBU in the European Union.
Concerns
- Selling, general and administrative expenses were $160 million for the second quarter of 2026, compared to $134 million for the same period of 2025.
- Research and development expenses were $82 million for the second quarter of 2026, compared to $78 million for the same period of 2025.
- Topline Phase 2 remlifanserin results in Alzheimer's disease psychosis remain anticipated in September to October 2026.
- Potential European Union commercialization of DAYBU remains contingent on approval by the European Commission.
What to watch
- Topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis anticipated September to October 2026.
- Progress in Phase 3 screening and enrollment for the RADIANT program.
- DAYBUE STIX uptake and patient demand.
- NUPLAZID new-to-brand prescription momentum following the expanded sales-force deployment.
- European Commission action on DAYBU following CHMP's positive opinion.
- Execution against full-year 2026 total revenue guidance of $1.24 to $1.30 billion.
Balance sheet and cash flow
- At June 30, 2026, cash, cash equivalents, and investment securities totaled $956 million, compared to $820 million at December 31, 2025.
Analysis
Acadia reported GAAP total revenues of $308 million for the second quarter of 2026, up 16% from $265 million in the second quarter of 2025. The release also described revenue growth of 17% compared with non-GAAP adjusted total revenues of $262 million in the second quarter of 2025. The non-GAAP adjustment relates to a change in estimate for NUPLAZID IRA rebate accruals.
Both commercial products contributed to the reported growth. NUPLAZID GAAP net product sales were $183 million, up 9% from $168 million, while DAYBUE net product sales were $125 million, an increase of 30% from $96 million. Management attributed DAYBUE performance to patient demand and uptake of DAYBUE STIX, and described NUPLAZID momentum in new-to-brand prescriptions as the expanded sales force gained traction.
Profitability remained positive, with GAAP net income of $32 million, or $0.18 per diluted share, compared with net income of $27 million, or $0.16 per diluted share, in the prior-year period. Quarterly R&D expense was $82 million compared with $78 million, and SG&A expense was $160 million compared with $134 million. Cash, cash equivalents, and investment securities totaled $956 million at June 30, 2026, compared with $820 million at December 31, 2025.
The company raised its full-year 2026 total-revenue guidance to $1.24 to $1.30 billion from $1.22 to $1.28 billion. It increased DAYBUE global net product sales guidance to $480 to $510 million from $460 to $490 million, reaffirmed NUPLAZID guidance of $760 to $790 million, and reduced R&D expense guidance to $355 to $380 million from $385 to $410 million. The principal near-term pipeline event is anticipated topline Phase 2 remlifanserin data in Alzheimer's disease psychosis during September to October 2026, alongside ongoing Phase 3 screening and enrollment.
Management, verbatim
Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis.
Catherine Owen Adams, Chief Executive Officer of Acadia
For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance.
Catherine Owen Adams, Chief Executive Officer of Acadia
For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field.
Catherine Owen Adams, Chief Executive Officer of Acadia
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss
- Non-GAAP net income and non-GAAP earnings per share
- Operating cash flow
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Prior-quarter operating results
- Full-year 2026 gross margin guidance
- Full-year 2026 tax-rate guidance
- A separately provided previous-release outlook for formal actual-versus-prior-guidance comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Acadia filed an SEC 8-K with Q2 2026 results and updated 2026 GAAP financial guidance, alongside clinical and regulatory updates for its neurology portfolio.
Ticker impact
Acadia raised full-year 2026 revenue guidance to $1.24 to $1.30 billion and reiterated NUPLAZID and DAYBUE sales ranges.
Likely positive bias for ACAD into the next trading sessions, with upside skew if investors view the guidance and Phase 2 timing as de-risking.
The filing is a primary disclosure (8-K) with specific, updated numeric guidance and concrete program milestones (Fast Track, enrollment completion, topline window).
Market effects
Reinforces demand and commercial momentum for CNS and rare-disease neurology franchises, potentially supporting sentiment toward profitable specialty pharma peers.
EMA positive opinion for DAYBUE could improve European uptake expectations for neurology rare-disease treatments.
Fast Track and EU marketing authorization path highlight continued regulatory progress for neuropsychiatric indications, relevant to global CNS pharma risk appetite.
Counterpoint
The guidance raise may already reflect known commercial trends, so the market may focus on whether Phase 2 remlifanserin topline in Sep-Oct can meet high expectations.
Key entities
- issuerAcadia Pharmaceuticals Inc.
Reported Q2 2026 financial results, updated 2026 revenue guidance, and provided clinical and regulatory updates.
- productDAYBUE (trofinetide)
Q2 GAAP net sales were $125 million, up 30% YoY; EMA CHMP adopted a positive opinion for Rett syndrome marketing authorization.
- productNUPLAZID (pimavanserin)
Q2 GAAP net sales were $183 million, up 9% YoY; guidance reaffirmed at $760 to $790 million for 2026.
- clinical_programremlifanserin
Phase 2 topline results expected Sep-Oct 2026; received FDA Fast Track designation for hallucinations and delusions in Alzheimer’s disease psychosis.
